Investment, Funding & Disinvestments

The company has invested nearly US$5 billion in the United States over the past 15 years, expanding its manufacturing, research, development, and distribution infrastructure.

The deal integrates Firefly Bio’s experimental Firelink degrader-antibody conjugate platform into J&J’s oncology research and development portfolio, marking a significant step in its long-term strategy to enhance targeted drug delivery systems.

The move comes as Teva advances plans to divest its API unit, Teva Active Pharmaceutical Ingredients (TAPI), a process first announced in January 2024.

The facility will occupy approximately 3,000 square metres and will comprise a ground floor, five upper levels, and a rooftop, reaching a height of 27.75 metres.

The acquisition comes as GSK intensifies its shift toward oncology to offset expected revenue pressure from upcoming patent expirations in its HIV franchise.

The deal was signed at the EAC Headquarters in Arusha, Tanzania, by EAC Secretary General Amb. Stephen P. Mbundi and KfW Development Bank Country Director for Tanzania and the EAC, Ms. Vanessa Eidt.

The expanded network enables the company to reach a broader customer base while strengthening its distribution capabilities across the UAE healthcare ecosystem.

Unlike most forms of dementia, which typically worsen gradually over many years, RPD progresses at an alarming pace and can lead to severe disability or death within one to two years.

The platform now enables the secure exchange of approvals, billing, and settlements among pharmacies, insurers, and healthcare providers, reducing reliance on manual paperwork by up to 98% in certain processes.

Under the agreement, EGT will oversee the rollout of Koios DS™ Breast and Koios DS™ Thyroid across key GCC markets, including the United Arab Emirates, Saudi Arabia, and Qatar.